Maximum toxicity to tumors.
Dosimetry-Guided Radiopharmaceutical Therapy (DG-RPT)
Fighting Cancer.
Making it Personal.
WHY IT MATTERS
For cancer patients, personalized radiopharmaceutical therapy (RPT) can mean increased tumor response, a higher quality of life and longer overall survival.
The Advantages of Dosimetry-Guided RPT
RPT provides an attractive alternative to chemotherapy, but one-size-fits-all dosing methods can result in under- or over-treatment. Dosimetry-guidance can unlock the full potential of RPT for patients.
Reduced damage to critical structures.
Improved survival.
Fewer side effects.
Torch™
GPU-Accelerated RPT Dose Assessment
Torch™ simplifies the otherwise complex task of analyzing a patient’s nuclear medicine scans to develop a personalized assessment, including estimates of patient-specific pharmacokinetics and calculation of dose to the patient’s tumors and critical structures.
NEWS & WEBINARS
- Mar 6, 2023
Voximetry Launches Clinical Operations Support to accelerate adoption of Torch® Dose Assessment and Dosimetry Services
- Feb 21, 2023
Voximetry Announces Experienced Commercial Leadership Hired for Launch of Torch® Dose Assessment in the U.S.
- Feb 3, 2023
Voximetry positions for growth with hiring of Chief Operating Officer Dr. Abhi Chakrabarti
- Dec 8, 2022
Pluvicto Demonstrates Clinical Benefit in Prostate Cancer Before Chemo